Answers are grounded in this paper and cite their sources.
Case report demonstrates sustained symptom and endoscopic improvement with dupilumab in Kartagener syndrome with refractory nasal polyps, suggesting a role for targeting type 2 inflammation.
Kartagener syndrome (KS) is a rare form of primary ciliary dyskinesia (PCD) characterized by chronic respiratory infections, bronchiectasis, chronic rhinosinusitis, and situs inversus. Evidence regarding biologic therapies in this setting is currently lacking. We report the case of a patient with KS and severe refractory chronic rhinosinusitis with nasal polyps (CRSwNP) treated with dupilumab after failure of conventional medical and surgical management. Treatment resulted in marked improvements in symptom burden, olfactory function, endoscopic findings, and quality of life, with sustained benefit throughout the 12-month follow-up. This observation suggests that type 2 inflammation may contribute to disease burden in selected patients with PCD and supports further investigation of biologic therapies in this challenging clinical setting.
No takes yet. Share an insight, caveat, or question.
Cristallo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: